Characteristics and management of patients with renal anaemia treated with daprodustat: an observational study in Japan.

IF 2.2 4区 医学 Q1 MEDICINE, GENERAL & INTERNAL
Masashi Takano, Kazuko Suzuki, Sakiyo Tsukamoto, Yasuo Nakajima, Hirofumi Ozeki, Masao Yarita, Ai Hayashi
{"title":"Characteristics and management of patients with renal anaemia treated with daprodustat: an observational study in Japan.","authors":"Masashi Takano, Kazuko Suzuki, Sakiyo Tsukamoto, Yasuo Nakajima, Hirofumi Ozeki, Masao Yarita, Ai Hayashi","doi":"10.1080/03007995.2025.2556321","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>HIF-PHI inhibitors, including daprodustat, have expanded treatment options for patients with renal anaemia in Japan. This analysis examines real-world utilization of daprodustat in Japan, for which data are currently lacking.</p><p><strong>Methods: </strong>This retrospective cohort study analyzed patient characteristics, treatment patterns, and management of renal anaemia in individuals aged >15 years who were treated with daprodustat between 1 August 2020 and 1 July 2023 using an anonymized electronic medical record database. Patients were assigned to dialysis-dependent (DD) and nondialysis-dependent (ND) cohorts.</p><p><strong>Results: </strong>This study included 1299 patients (111 DD cohort; 1188 ND cohort). Mean age was 71.0 and 79.2 years in the DD and ND cohorts, respectively. In both cohorts, hypertension, heart failure, oesophageal gastric erosion, and type 2 diabetes mellitus were frequent comorbidities. In the DD cohort, 31.5% of patients had Hb levels of 9-10 g/dL at baseline and in the ND cohort 35.9% had Hb levels <9 g/dL at baseline. Prior to the index date, 72 patients in the DD cohort (64.9%) and 635 patients (53.5%) in the ND cohort were treated for anaemia. In patients who switched from erythropoiesis-stimulating agents to daprodustat, mean haemoglobin increased from 9.9 g/dL at baseline to 10.8 g/dL in the DD cohort (<i>n</i> = 23; Wilcoxon sign-ranked test [WSRT] <i>p</i> = 0.0148) and from 9.6 g/dL at baseline to 10.4 g/dL in the ND cohort (<i>n</i> = 92; WSRT <i>p</i> < 0.0001) 28 weeks after daprodustat initiation.</p><p><strong>Conclusion: </strong>Approximately a third (DD) to almost half (ND) of patients with renal anaemia were not receiving treatment for anaemia. An increase in haemoglobin levels was observed after initiation of daprodustat, including in patients previously treated with erythropoiesis-stimulating agents, however causality cannot be confirmed due to lack of a control group.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-10"},"PeriodicalIF":2.2000,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Medical Research and Opinion","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/03007995.2025.2556321","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: HIF-PHI inhibitors, including daprodustat, have expanded treatment options for patients with renal anaemia in Japan. This analysis examines real-world utilization of daprodustat in Japan, for which data are currently lacking.

Methods: This retrospective cohort study analyzed patient characteristics, treatment patterns, and management of renal anaemia in individuals aged >15 years who were treated with daprodustat between 1 August 2020 and 1 July 2023 using an anonymized electronic medical record database. Patients were assigned to dialysis-dependent (DD) and nondialysis-dependent (ND) cohorts.

Results: This study included 1299 patients (111 DD cohort; 1188 ND cohort). Mean age was 71.0 and 79.2 years in the DD and ND cohorts, respectively. In both cohorts, hypertension, heart failure, oesophageal gastric erosion, and type 2 diabetes mellitus were frequent comorbidities. In the DD cohort, 31.5% of patients had Hb levels of 9-10 g/dL at baseline and in the ND cohort 35.9% had Hb levels <9 g/dL at baseline. Prior to the index date, 72 patients in the DD cohort (64.9%) and 635 patients (53.5%) in the ND cohort were treated for anaemia. In patients who switched from erythropoiesis-stimulating agents to daprodustat, mean haemoglobin increased from 9.9 g/dL at baseline to 10.8 g/dL in the DD cohort (n = 23; Wilcoxon sign-ranked test [WSRT] p = 0.0148) and from 9.6 g/dL at baseline to 10.4 g/dL in the ND cohort (n = 92; WSRT p < 0.0001) 28 weeks after daprodustat initiation.

Conclusion: Approximately a third (DD) to almost half (ND) of patients with renal anaemia were not receiving treatment for anaemia. An increase in haemoglobin levels was observed after initiation of daprodustat, including in patients previously treated with erythropoiesis-stimulating agents, however causality cannot be confirmed due to lack of a control group.

日本的一项观察性研究:达生产司他治疗肾性贫血患者的特点和管理。
目的:HIF-PHI抑制剂,包括达普达司他,扩大了日本肾性贫血患者的治疗选择。本分析考察了日本目前缺乏数据的daproducstat的实际使用情况。方法:本回顾性队列研究使用匿名电子病历数据库,分析2020年8月1日至2023年7月1日期间接受达生产他治疗的bb0 ~ 15岁患者肾性贫血的患者特征、治疗模式和管理。患者被分为透析依赖组(DD)和非透析依赖组(ND)。结果:本研究纳入1299例患者(DD队列111例;ND队列1188例)。DD组和ND组的平均年龄分别为71.0岁和79.2岁。在这两个队列中,高血压、心力衰竭、食管胃糜烂和2型糖尿病是常见的合并症。在DD队列中,31.5%的患者在基线时Hb水平为9-10 g/dL, ND队列中35.9%的患者Hb水平为n = 23;结论:大约三分之一(DD)到近一半(ND)的肾性贫血患者没有接受贫血治疗。在开始使用达生产司他后,观察到血红蛋白水平升高,包括先前接受过促红细胞生成药物治疗的患者,但由于缺乏对照组,无法确认因果关系。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current Medical Research and Opinion
Current Medical Research and Opinion 医学-医学:内科
CiteScore
4.40
自引率
4.30%
发文量
247
审稿时长
3-8 weeks
期刊介绍: Current Medical Research and Opinion is a MEDLINE-indexed, peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, Phase II-IV studies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged. Preclinical, Phase I, pharmacoeconomic, outcomes and quality of life studies may also be considered if there is clear clinical relevance
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信